Results 51 to 60 of about 260,030 (390)

RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. [PDF]

, 2013
ObjectiveTo determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy.BackgroundRAS mutation has been reported ...
Aloia, Thomas A, Andreou, Andreas, Chen, Su S, Curley, Steven A, Kopetz, Scott E, Maru, Dipen M, Shindoh, Junichi, Vauthey, Jean-Nicolas, Zimmitti, Giuseppe   +8 more
core   +1 more source

Utility of KRAS Gene and Clinicopathological Features in the Assessment of the Risk of Type 2 Diabetes in the Etiology of Colon Cancer

Global Medical Genetics, 2020
Background Cancer and diabetes have a tremendous impact on health globally. This study aimed to evaluate the KRAS gene in colon cancer tissues obtained from patients with type 2 diabetes mellitus (T2DM).
Wedad Saeed Al-Qahtani, Ebtesam Al-Olayan, Fatimah Gh. Albani, Rania Saad Suliman, Nada Hamad Aljarba, E.M. Al-Humaidhi, Alanood S. Almurshedi, Dalia Mostafa Domiaty, Manal Abdullah Alduwish, Aljohara M. Al-Otaibi, Abdelbaset Mohamed Elasbali, Hussain Gadelkarim Ahmed, Bassam Ahmed Almutlaq   +12 more
doaj   +1 more source

Molecular-genetic mechanisms of the signal cascade RAS-RAF-MEK-ERK associated with the development of the tumor process and the purpose of targeted drugs for colorectal cancer

Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, 2021
Colorectal cancer occupies one of the leading positions in the world in the structure of cancer incidence. The vital processes of cancer cells largely depend on the production of growth factors and their receptors. One of these is epidermal growth factor
A. N. Toropovsky, O. N. Pavlova, D. A. Viktorov, A. G. Nikitin   +3 more
doaj   +1 more source

KRAS as a Therapeutic Target [PDF]

Clinical Cancer Research, 2015
Abstract KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by ...
openaire   +5 more sources

On the prevalence of KRAS mutations in GISTs [PDF]

Virchows Archiv, 2013
Dear Editor, In our commentary entitled “GISTogram: a graphic presentation of the growing GIST complexity,” recently published in Virchows Archiv [1], on the basis of an extrapolation from a naive GIST cohort from Ticino, Switzerland [2], we proposed a possible 4 % prevalence of KRAS mutations in GISTs. A recent paper by Lasota et al.
Ricci, Riccardo, Dei Tos, Ap, Rindi, Guido   +2 more
openaire   +3 more sources

Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma.

Clinical Cancer Research, 2022
PURPOSE KRAS mutation (MT) is a major oncogenic driver in PDAC. A small subset of PDACs harbor KRAS-wild-type (WT). We aim to characterize the molecular profiles of KRAS-WT PDAC to uncover new pathogenic drivers and offer targeted treatments ...
P. Philip, I. Azar, J. Xiu, M. Hall, A. Hendifar, Emil Lou, Jimmy J. Hwang, J. Gong, R. Feldman, Michelle Ellis, P. Stafford, D. Spetzler, M. Khushman, D. Sohal, A. Lockhart, B. Weinberg, W. El-Deiry, J. Marshall, A. Shields, W. Korn   +19 more
semanticscholar   +1 more source

KRAS: Druggable at Last

The Oncologist, 2023
The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
Benjamin O Herzberg, Gulam A Manji
openaire   +2 more sources

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma [PDF]

, 2018
Pancreatic cancer is characterized by nearly universal activating mutations in KRAS. Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
Daylan, Ayse Ece Cali, Del Vecchio, Annachiara, Espinoza, Carlos, Fabo, Tania, Fearon, Eric R., Feng, Ying, Galbán, Stefanie, Halbrook, Christopher J., Karim, Saadia A., Kovalenko, Ilya, Kremer, Daniel M., Kumar-Sinha, Chandan, Lee, Ho-Joon, Ljungman, Mats, Lyssiotis, Costas A., Magnuson, Brian, Morton, Jennifer P., Pasca di Magliano, Marina, Schofield, Heather K., Yan, Wei, Zeller, Jörg   +20 more
core   +1 more source

Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer [PDF]

Archives of Razi Institute, 2022
In carcinogenesis, KRAS is an essential oncogene that plays a key function. The polymorphism of rs61764370 is a candidate for cancer susceptibility in KRAS3' untranslated region.
M Ghazi Jumaa
doaj   +1 more source

KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge

Cell Discovery, 2022
KRAS mutation occurs in nearly 30% of human cancers, yet the most prevalent and oncogenic KRAS(G12D) variant still lacks inhibitors. Herein, we designed a series of potent inhibitors that can form a salt bridge with KRAS’s Asp12 residue.
Zhongwei Mao, Hongying Xiao, Panpan Shen, Yu Yang, Jing Xue, Yunyun Yang, Yanguo Shang, Lilan Zhang, Xin Li, Yuying Zhang, Yanan Du, Chun-Chi Chen, R. Guo, Yonghui Zhang   +13 more
semanticscholar   +1 more source